AIM: To illustrate clinicopathological features of orbital non-rhabdomyosarcoma soft tissue sarcoma (NRSTS), and to compare the treatment outcome between postoperative radiotherapy (RT) and chemotherapy in a retrospective analysis nearly 20y. METHODS: A retrospective cohort study of 56 patients with orbital NRSTS were reviewed, 34 of whom received postoperative RT, and 22 received postoperative chemotherapy. The clinicopathological features, local recurrence, metastases, and survival data were recorded. Survival analysis was performed using the Kaplan-Meier method. RESULTS: During follow-up (111.8mo, ranged 8-233mo) for 56 patients, 19 patients of them developed local recurrence, and 7 patients developed distant metastases. Fifteen patients died during follow-up period. Overall survival rates considering the whole study group was 78.57% at 5y, and 72.16% at 10y after the initial diagnosis. Compared with chemotherapy, RT was associated with lower risk of local recurrence [hazard ratio for RT vs chemotherapy, 0.263, 95% confidence interval (CI), 0.095-0.728, P=0.0015]; with lower risk of distant metastasis (hazard ratio for RT vs chemotherapy, 0.073, 95%CI, 0.015-0.364, P=0.0014); and with lower risk of death from disease (hazard ratio for RT vs chemotherapy, 0.066, 95%CI, 0.022-0.200, P<0.0001). The 5-year survival rate in RT group was 97.06% compared to 50% in chemotherapy group. CONCLUSION: In patients with orbital NRSTS, postoperative RT provides better control of local recurrence, distant metastasis, and death from disease than chemotherapy. RT is the more preferrable adjuvant therapy compared to chemotherapy possibly.

中文翻译：

---

眼眶非横纹肌肉瘤软组织肉瘤的辅助治疗：放疗与化疗的长期疗效比较

目的：通过回顾性分析近20年眼眶非横纹肌肉瘤软组织肉瘤（NRSTS）的临床病理特征，比较术后放疗（RT）与化疗的治疗效果。方法：对 56 例眼眶 NRSTS 患者进行回顾性队列研究，其中 34 例接受术后放疗，22 例接受术后化疗。记录临床病理特征、局部复发、转移和生存数据。使用Kaplan-Meier方法进行生存分析。结果：56例患者随访111.8mo，8～233mo，其中19例出现局部复发，7例出现远处转移。随访期间有 15 名患者死亡。考虑到整个研究组，初次诊断后 5 年的总生存率为 78.57%，10 年的总生存率为 72.16%。与化疗相比，放疗与较低的局部复发风险相关[放疗与化疗的风险比，0.263，95%置信区间（CI），0.095-0.728，P=0.0015]；远处转移风险较低（放疗与化疗的风险比，0.073，95%CI，0.015-0.364，P=0.0014）；因疾病死亡的风险较低（放疗与化疗的风险比，0.066，95%CI，0.022-0.200，P<0.0001）。放疗组的5年生存率为97.06%，而化疗组的5年生存率为50%。结论：对于眼眶 NRSTS 患者，术后放疗比化疗能更好地控制局部复发、远处转移和疾病死亡。与化疗相比，放疗可能是更优选的辅助治疗。